clinical trial · NCT06869785
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Relapsing Multiple Sclerosis (RMS)Ofatumumab approved doseOfatumumab new dose
brief summary
This study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new dosage of ofatumumab compared to the approved dosage of ofatumumab followed by extended treatment in participants with relapsing multiple sclerosis.
started
Mar 13, 2025
primary completion
Jan 28, 2026
completion
Mar 23, 2030
last updated
Apr 21, 2026
detailed description
This is a Phase 3, open label, parallel-group, multicenter study in participants with relapsing multiple sclerosis
official title
An Open-label, Randomized, Parallel Group, Non-inferiority Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab, Followed by Extended Treatment in Participants With Relapsing Multiple Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol